{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029438","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.500665+00:00","generated_at":"2026-06-13T19:34:17.987491+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sarepta sets wholesale acquisition cost for ELEVIDYS at $3.2 million","bullets":["Wholesale acquisition cost (gross price) of gene therapy ELEVIDYS set at $3.2 million.","Indicated for ambulatory pediatric patients aged 4-5 years with DMD gene mutation.","Price disclosed during investor webcast on June 22, 2023.","NASDAQ ticker: SRPT."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029438","json":"https://secwatch.observer/filing/0000950170-23-029438.json","markdown":"https://secwatch.observer/filing/0000950170-23-029438.md","text":"https://secwatch.observer/filing/0000950170-23-029438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000095017023029438/0000950170-23-029438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000095017023029438/srpt-20230622.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:34:17.987491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}